Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: Am J Transplant. 2019 Jul 24;20(1):75–87. doi: 10.1111/ajt.15517

Figure 5. Antigen-specific TCR transgenic cTfh cells display similar phenotypic characteristics and kinetics to endogenous alloreactive cTfh cells following transplantation.

Figure 5.

(A) Naïve B6 mice were adoptively transferred 106 of each Thy1.1+ CD4+ OT-II and CD8+ OT-I T cells, transplanted skin from B6 (Syn) or mOVA donors and sacrificed at indicated time points post-transplantation for PBMC, graft-dLN and serum analyses. (B) Flow plots (gated on CD4+Foxp3 T cells) depict gating strategy for CXCR5+Thy1.1+ OVA-specific cTfh cells. (C) Summary data of Thy1.1+ cTfh cell frequencies and numbers following B6 (Syn) or mOVA skin transplantation over time (n=5 per group). (D) Summary data of phenotypic marker expression in naïve (CD44loCD62L+) OT-II cells, and Thy1.1+ CXCR5 or CXCR5+ OT-II cells from the peripheral blood 10 days post-transplantation (n=5 per group). (E) Flow plots depicting ICOS and PD-1 expression on naive OT-II cells on day 0 and Thy1.1+CXCR5+ cTfh cells 10 days post-transplantation. (F) Summary data of the frequencies of ICOS+PD-1+ of naïve OT-II cells on day 0 and Thy1.1+ cTfh cells 10 days after transplant (n=5 per group). (G) Summary data of ICOS+PD-1+ Thy1.1+ cTfh cell frequencies over time (n=5 per group). Summary data of (H) Thy1.1+ cTfh cell and (I) ICOS+PD-1+ Thy1.1+ cTfh cell frequencies relative to anti-OVA IgG formation over time (n=5 per group). Summary data represent mean (SE) and are representative of three independent experiments with a total of 10–15 mice per group. *p < 0.05, **p < 0.01, ***p< 0.001.